Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.
A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.
Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.
As authorities record data on the largest US measles outbreak in decades, 79% of Americans support school vaccine mandates for children, an encouraging result.